SHANGHAI FOREFRONT PHARMCEUTICAL CO LTD has a total of 14 patent applications. It decreased the IP activity by 50.0%. Its first patent ever was published in 2016. It filed its patents most often in China, WIPO (World Intellectual Property Organization) and EPO (European Patent Office). Its main competitors in its focus markets organic fine chemistry, pharmaceuticals and environmental technology are NANJING MINGDE DRUG R & D CO LTD, JIANGSU NHWA PHARMACEUTICAL CO LTD and VIRONOVA AB.
# | Country | Total Patents | |
---|---|---|---|
#1 | China | 7 | |
#2 | WIPO (World Intellectual Property Organization) | 5 | |
#3 | EPO (European Patent Office) | 1 | |
#4 | Republic of Korea | 1 |
# | Industry | |
---|---|---|
#1 | Organic fine chemistry | |
#2 | Pharmaceuticals | |
#3 | Environmental technology |
# | Name | Total Patents |
---|---|---|
#1 | Li Wei | 14 |
#2 | Ren Yi | 10 |
#3 | Fu Shaojun | 9 |
#4 | Huang Chengjun | 8 |
#5 | Wei Zhewen | 7 |
#6 | Zhu Yanyan | 5 |
#7 | Wang Qiong | 5 |
#8 | Fu Gang | 5 |
#9 | Zhang Xixuan | 4 |
#10 | Yang Xin'An | 2 |
Publication | Filing date | Title |
---|---|---|
CN106831737A | The preparation of Wei Patawei and its derivative | |
CN106432253A | New crystal form of Velpatasvir and preparation method of new crystal form | |
CN106432197A | Ledipasvir midbody monomer tosilate and crystal form and preparation method thereof | |
CN106220617A | A kind of new synthetic method of his Wei of Dacca | |
CN106220639A | A kind of Wei Patawei intermediate novel crystal forms | |
WO2017005104A1 | Novel ledipasvir crystal form and preparation method thereof | |
KR20170131508A | METHOD FOR PREPARING LEDIPHASBIR AND ITS DERIVATIVES AND INTERMEDIATE COMPOUND FOR THE PREPARATION OF REDIPASVIR | |
CN105566303A | Novel daclatasvir crystal form and preparing method thereof |